Cardiology and Therapy (Feb 2024)

Cerebral Embolic Protection in Transcatheter Aortic Valve Implantation Using the Sentinel Cerebral Protection System: A Systematic Review and Meta-Analysis

  • Wissam Harmouch,
  • Barbara Karnkowska,
  • Ravi Thakker,
  • Peter Rasmussen,
  • Mostafa Shalaby,
  • Wissam Khalife,
  • Haider Alwash,
  • Afaq Motiwala,
  • Paul Kumfa,
  • Syed Gilani,
  • Hani Jneid,
  • Umamahesh Rangasetty

DOI
https://doi.org/10.1007/s40119-024-00359-4
Journal volume & issue
Vol. 13, no. 2
pp. 299 – 314

Abstract

Read online

Abstract Introduction Transcatheter aortic valve implantation (TAVI) plays a vital role in patients with symptomatic aortic stenosis. Despite the mortality benefit of TAVI, embolic stroke remains a feared complication. As a result, transcatheter cerebral embolic protection (TCEP) devices have been developed to reduce this risk. Given the ongoing debate of TCEP in TAVI, we performed a systematic review and meta-analysis of all randomized controlled trials to date to identify outcomes of periprocedural stroke using the Sentinel™ cerebral protection system (CPS). Methods MEDLINE, Cochrane, and Scopus databases were utilized from inception until 12/2023. PRISMA criteria was utilized. Keywords included “cerebral embolic protection”, “sentinel cerebral protection system”, “transcatheter aortic valve implantation”, and “transcatheter aortic valve replacement”. Primary outcome was periprocedural stroke. Secondary outcomes included periprocedural disabling and non-disabling stroke, all-cause mortality, transient ischemic attack, delirium, acute kidney injury, vascular complications, bleeding, and pacemaker implantation. Risk ratios (RR) were measured via Mantel–Haenszel method with fixed analysis. Heterogeneity was assessed via chi-squared and Higgin’s I 2 test. Results Four trials with 3528 patients were assessed. SAPIEN 3 was the most common bioprosthetic valve used. The average age was 79.4 years with 41.9% of the sample size being females. The most prevalent comorbidities were hypertension, diabetes mellitus, and coronary artery disease. There was no difference in periprocedural stroke in patients who underwent TAVI with the Sentinel™ CPS compared to no TCEP (RR 0.75, P = 0.12). Periprocedural disabling strokes were less likely in those who underwent TAVI with the Sentinel™ CPS compared to no TCEP (RR 0.41, P = 0.02) with a number needed to treat (NNT) of 123. All other outcomes did not reach statistical significance. Conclusions In our analysis, there was no difference between TAVI with the Sentinel™ CPS compared to TAVI without TCEP in regard to risk of periprocedural stroke; however, it was associated with a decreased risk of periprocedural disabling stroke.

Keywords